Travere director granted shares and options

Travere Therapeutics director Ron Squarer received new equity compensation.

Rhea-AI Filing Summary

Travere Therapeutics director Ron Squarer received new equity compensation. He was granted 4,000 shares of common stock as an automatic equity grant under the company’s 2018 Equity Incentive Plan, pursuant to the non-employee director compensation program. Following this award, he directly holds 39,375 common shares.

Squarer was also granted stock options covering 12,000 shares of common stock with a conversion price of $42.26 per share. The equity award vests over a one-year period, and the options are exercisable from May 2027 and expire in May 2036, reflecting routine board-level compensation rather than open-market trading.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 2 txns

Insider Squarer Ron

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	12,000	$0.00	$0.00
Grant/Award	Common Stock	4,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 12,000 contracts (Direct); Common Stock — 39,375 shares (Direct)

Footnotes (2)

1. F1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
2. F2. The equity award vests over a one year period.

Key Figures

Common stock grant: 4,000 shares Total shares held: 39,375 shares Option grant size: 12,000 options +4 more

7 metrics

Common stock grant 4,000 shares Automatic equity grant to Ron Squarer on May 19, 2026

Total shares held 39,375 shares Ron Squarer’s direct common stock holdings after grant

Option grant size 12,000 options Stock option (right to buy) granted May 19, 2026

Option exercise price $42.26 per share Conversion or exercise price for 12,000 options

Option exercisability date May 19, 2027 Exercise date for stock options granted to Squarer

Option expiration date May 19, 2036 Expiration of 12,000 stock options

Vesting period One year Vesting schedule for the equity award

Key Terms

automatic equity grant, 2018 Equity Incentive Plan, non-employee director compensation program, stock option (right to buy), +1 more

5 terms

automatic equity grant financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

2018 Equity Incentive Plan financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

non-employee director compensation program financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program."

stock option (right to buy) financial

"Stock option (right to buy) listed as a derivative security with a conversion price of 42.2600."

equity award vests financial

"The equity award vests over a one year period."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity did Ron Squarer receive in Travere Therapeutics (TVTX)?

Ron Squarer received a grant of 4,000 Travere Therapeutics common shares and stock options over 12,000 shares. These awards are part of the non-employee director compensation program under the company’s 2018 Equity Incentive Plan.

Is Ron Squarer’s Form 4 for TVTX an open-market purchase or sale?

The Form 4 reports equity grants, not open-market trades. Squarer received 4,000 common shares and 12,000 stock options as compensation, with no cash purchase or sale reported in these transactions.

What is the strike price and term of Ron Squarer’s Travere options?

Squarer’s stock options cover 12,000 Travere Therapeutics common shares at a conversion price of $42.26 per share. The options become exercisable in May 2027 and expire in May 2036, providing a long-dated incentive.

How many Travere Therapeutics shares does Ron Squarer hold after this grant?

After receiving the new equity grant, Ron Squarer directly holds 39,375 Travere Therapeutics common shares. This figure reflects his post-transaction position as reported in the Form 4 filing.

How does the Travere equity award to Ron Squarer vest?

The equity award to Ron Squarer vests over a one-year period. This applies to the automatic equity grant provided under Travere Therapeutics’ 2018 Equity Incentive Plan for non-employee directors, aligning compensation with ongoing board service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Squarer Ron

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		4,000(1)(2)	A	$0	39,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$42.26	05/19/2026		A		12,000(1)		05/19/2027(2)	05/19/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

2. The equity award vests over a one year period.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)